Quantcast

Latest adenosine Stories

2014-09-22 08:28:11

Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results...

2014-06-09 08:28:15

- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic...

2014-06-09 08:28:13

-Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/ -- OphthaliX Inc. (OTCQB: OPLI), announced today an update on its clinical developments and strategic plans: -- Glaucoma - The Company is focused on the development of CF101 for the treatment of glaucoma, with a Phase II study ongoing in Israel and Europe. The Company intends to...

Alzheimer's Disease
2014-04-07 08:44:44

University of Bonn A team of researchers working with Prof. Dr. Christa E. Muller from the University of Bonn demonstrates a positive effect on tau deposits As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. The two-years project was supported with 30,000 Euro from...

Heart Attack Patients May Soon Have Side Effect-Free Drug Option
2014-03-12 06:36:52

April Flowers for redOrbit.com - Your Universe Online A new drug designed to stop a heart attack in its tracks, while reducing the damage caused, all without side effects, is one step closer to development thanks to a group of Melbourne scientists from Monash University. New hope for thousands of people who experience heart attacks and heart failure is provided by the study, published in a recent issue of Proceedings of the National Academy of Sciences. A team of scientists, led by...

2013-12-31 08:22:46

Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following: The Company's subsidiary, OphthaliX Inc. (OTCQB: OPLI), will conduct a retrospective analysis...

2013-12-31 08:22:44

PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related